# EDGAR Filing Document

**Accession Number:** 0000010456
**File Stem:** 0001628280-25-053056
**Filing Date:** 2025-11
**Character Count:** 25887
**Document Hash:** 44870d0d6c79b5165b612f91188db7b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-053056.hdr.sgml**: 20251119

**ACCESSION NUMBER**: 0001628280-25-053056

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251119

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251119

**DATE AS OF CHANGE**: 20251119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BAXTER INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000010456
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 360781620
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-04448
- **FILM NUMBER:** 251496734

**BUSINESS ADDRESS:**
- **STREET 1:** ONE BAXTER PARKWAY
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015
- **BUSINESS PHONE:** 2249482000

**MAIL ADDRESS:**
- **STREET 1:** ONE BAXTER PARKWAY
- **CITY:** DEERFIELD
- **STATE:** IL
- **ZIP:** 60015

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BAXTER TRAVENOL LABORATORIES INC
- **DATE OF NAME CHANGE:** 19880522

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BAXTER LABORATORIES INC
- **DATE OF NAME CHANGE:** 19760608

?xml version='1.0' encoding='ASCII'? bax-20251119

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 19, 2025**

**Baxter International Inc.** 

**(Exact name of registrant as specified in its charter)**

---

| |
|:---|
| **Delaware** |
| **(State or other jurisdiction**<br>**of incorporation)** |

---

---

| | |
|:---|:---|
| **1-4448** | **36-0781620** |
| **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| **One Baxter Parkway, Deerfield, Illinois** | **60015** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(224) 948-2000**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, $1.00 par value** | **BAX (NYSE)** | **New York Stock Exchange** |
| **1.3% Global Notes due 2029** | **BAX 29** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐

------

**Item 8.01 Other Events.**

On November 19, 2025, Baxter International Inc. (the "Company") issued a press release announcing the commencement of cash tender offers (each, a "Tender Offer" and together, the "Tender Offers") of (i) any and all of its 2.600% senior unsecured notes due 2026 (the "2026 Notes") and (ii) a portion of its 1.915% senior unsecured notes due 2027 (the "2027 Notes") in an aggregate purchase price up to $300 million (which amount is subject to increase, decrease or elimination in accordance with the terms of the Company's related offer to purchase (as discussed below), and together with the 2026 Notes, the "Notes"). A copy of the press release announcing the Tender Offers is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

This Current Report on Form 8-K, including the press release incorporated by reference, is neither an offer to sell nor a solicitation of offers to buy any Notes. The Tender Offers are being made only pursuant to the offer to purchase of the Company, dated November 19, 2025. The Tender Offers are not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 <u>[Press Release Dated](exhibit991-8xk.htm) [November](exhibit991-8xk.htm) [19](exhibit991-8xk.htm) [, 2025](exhibit991-8xk.htm)</u>

(104) Cover Page Interactive Data File (embedded within the Inline XBRL document)

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | Baxter International Inc. | Baxter International Inc. |
| | By: | /s/ Joel T. Grade |
| | Name:  | Joel T. Grade |
| Date: November 19, 2025 | Title:  | Executive Vice President and Chief Financial Officer |

---

## Ex-99

**Exhibit 99.1**

![baxterlogo.jpg](baxterlogo.jpg)

**BAXTER ANNOUNCES TENDER OFFERS FOR 2026 NOTES AND 2027 NOTES**

DEERFIELD, Ill., Nov. 19, 2025 - Baxter International Inc. (NYSE:BAX) ("<u>Baxter</u>" or the "<u>Company</u>") today announced the commencement of tender offers, subject to the terms and conditions described below, to purchase for cash the debt securities issued by Baxter listed in the table below (collectively, the "<u>Securities</u>" and each a "<u>series</u>"). Subject to market conditions, the tender offers are expected to be funded using a portion of the proceeds from a concurrent offering of senior unsecured notes by the Company (the "<u>New Notes</u>"). The Company intends to use the remaining proceeds from the concurrent public offering of the New Notes to repay other indebtedness, including any remaining 2026 Notes and its outstanding term loan credit facility which had an outstanding balance of $645 million as of Sept. 30, 2025.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Title of Security** | **CUSIP Number**<sup>(1)</sup> | **Principal Amount Outstanding** | **U.S. Treasury Reference Security** | **Bloomberg Reference Page** | **Fixed Spread** | **Early Tender Payment** <sup>(3)(4)</sup> | **Maximum Tender Cap** |
| 2.600% Senior Unsecured Notes due 2026 | 071813 BQ1 | $750000000 | UST 1.500% <br>due Aug. 15, 2026 | FIT3 | +30 bps | $30 | N/A |
| 1.915% Senior Unsecured Notes due 2027 | 071813CL1; U07181BD; 071813CJ6 | $1450000000 | UST 4.125% <br>due Jan. 31, 2027 | FIT4 | +40 bps | $30 | $300000000 |

---

(1)CUSIPs are provided for the convenience of Holders. No representation is made as to the correctness or accuracy of such numbers.

(2)The Bloomberg Reference Pages are provided for convenience only. To the extent any Bloomberg Reference Page changes prior to the Price Determination Date (as defined below), the Dealer Managers referred to below will quote the applicable Reference Treasury Security from such updated Bloomberg Reference Page.

(3)Per $1,000 amount.

(4)The Total Consideration for Securities validly tendered prior to or at the applicable Early Tender Date (as defined below) and accepted for purchase is calculated using the applicable Fixed Spread and is inclusive of the Early Tender Payment.

The terms and conditions of the Tender Offers (as defined below) are described in the offer to purchase, dated Nov. 19, 2025 (as it may be amended or supplemented from time to time, the "<u>Offer to Purchase</u>"). Each of the Tender Offers is subject to the satisfaction of certain conditions as set forth in the Offer to Purchase, including the applicable portion of the Financing Condition. Baxter is offering to purchase for cash (a) any and all of its 2.600% senior unsecured notes due 2026 (the "<u>2026 Notes</u>") (the "<u>Any and All Tender Offer</u>") and (b) a portion of its 1.915% senior unsecured notes due 2027 (the "<u>2027 Notes</u>") in an aggregate purchase price up to $300 million (such cap, the "<u>Maximum Tender Cap</u>") (the "<u>Maximum Tender Offer</u>" and, together with the Any and All Tender Offer, the "<u>Tender Offers</u>"). Baxter reserves the right, but is under no obligation, to increase the Maximum Tender Cap with respect to the 2027 Notes at any time, subject to applicable law. The Company refers investors to the Offer to Purchase for the complete terms and conditions of the Tender Offers.

The Tender Offers will expire at 5:00 p.m., New York City time, on Dec. 18, 2025, or any other date and time to which the Company extends the applicable Tender Offer (such date and time, as it may be extended with respect to a Tender Offer, the applicable "<u>Expiration Date</u>"), unless earlier terminated. Holders of Securities must validly tender and not validly withdraw their Securities prior to or at 5:00 p.m., New York City time, on Dec. 3, 2025 (such date and time, as it may be extended with respect to a Tender Offer, the applicable "<u>Early Tender Date</u>"), to be eligible to receive the applicable Total

------

Consideration (as defined below), which is inclusive of an amount in cash equal to the applicable amount set forth in the table above under the heading "Early Tender Payment" (the applicable "<u>Early Tender Payment</u>"), plus Accrued Interest. If a holder validly tenders Securities after the applicable Early Tender Date but prior to or at the applicable Expiration Date, the holder will only be eligible to receive the applicable Late Tender Offer Consideration (as defined below) plus Accrued Interest.

The applicable consideration (the "<u>Total Consideration</u>") offered per $1,000 principal amount of each series of Securities validly tendered and accepted for purchase pursuant to the applicable Tender Offer will be determined in the manner described in the Offer to Purchase by reference to the applicable fixed spread for such Securities specified in the table above plus the applicable yield based on the bid-side price of the applicable U.S. Treasury Reference Security specified in the table above as displayed on the applicable page on the Bloomberg Bond Trader FIT3 and FIT4 series of pages at 10:00 a.m., New York City time, on Dec. 4, 2025 (the "<u>Price Determination Date</u>"). The "Late Tender Offer Consideration" is equal to the Total Consideration minus the Early Tender Payment.

The Tender Offers will expire on the applicable Expiration Date. Except as set forth below, payment for the Securities that are validly tendered prior to or at the Expiration Date will be made on a date promptly following such Expiration Date, which is currently anticipated to be Dec. 22, 2025. The Company reserves the right, in its sole discretion, to make payment for Securities that are validly tendered prior to or at the applicable Early Tender Date and that are accepted for purchase on an earlier settlement date, which, if applicable, is currently anticipated to be Dec. 8, 2025, provided that the conditions to the satisfaction of the applicable Tender Offer are satisfied, including the applicable portion of the Financing Condition.

Holders will also receive accrued and unpaid interest on Securities validly tendered and accepted for purchase from the applicable last interest payment date up to, but not including, the applicable settlement date of each Tender Offer ("<u>Accrued Interest</u>").

To the extent the Any and All Tender Offer is completed but less than all of the outstanding 2026 Notes are tendered and accepted for purchase in the Tender Offers, the Company intends to satisfy and discharge its obligations under the 2026 Notes and the applicable indenture in accordance with the terms thereof and solely with respect to the 2026 Notes.

Tendered Securities may be validly withdrawn prior to or at, but not after, 5:00 p.m., New York City time, on Dec. 3, 2025.

**Information Relating to the Tender Offers**

Each of the Tender Offers is subject to the satisfaction or waiver of certain conditions, including the applicable portion of the Financing Condition, which is specified in the Offer to Purchase. The Tender Offers are not conditioned upon the tender of any minimum principal amount of the Securities.

The Offer to Purchase is being distributed to holders beginning today. Citigroup Global Markets Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC are the dealer managers for the Tender Offers. Investors with questions regarding the Tender Offers may contact Citigroup Global Markets Inc. at (800) 558-3745 (toll-free), BofA Securities at debt_advisory@bofa.com or by calling toll-free at (888) 292-0070 or collect at (980) 387-3907 or J.P. Morgan Securities LLC at (866) 834-4666 (toll-free) or (212) 834-3554 (collect). D.F. King & Co., Inc. is the tender and information agent for the Tender Offers and can be contacted at (866) 227-7300 (toll-free) or (646) 852-9043 (collect).

None of the Company or its affiliates, their respective boards of directors, the dealer managers, the tender and information agent or the trustee with respect to any series of Securities is making any recommendation as to whether holders should tender any Securities in response to any of the Tender Offers, and neither the Company nor any such other person has authorized any person to make any such recommendation. Holders must make their own decisions as to whether to tender any of their Securities, and, if so, the principal amount of Securities to tender.

The full details of the Tender Offers, including complete instructions on how to tender Securities, are included in the Offer to Purchase. Holders are strongly encouraged to read carefully the Offer to Purchase, including materials incorporated by reference therein, because they will contain important

------

information. The Offer to Purchase may be obtained from D.F. King & Co., Inc., free of charge by calling toll-free at (866) 227-7300 (bankers and brokers can call collect at (646) 852-9043).

This press release shall not constitute an offer to purchase or a solicitation of an offer to purchase the 2026 Notes or the 2027 Notes. The Tender Offers are being made solely pursuant to the Offer to Purchase. In addition, this press release shall not constitute an offer to sell, or a solicitation of an offer to buy, the New Notes or any other security, and shall not constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful.

**About Baxter**

At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond.

**Forward-Looking Statements**

*This release includes forward-looking statements (including ones related to the Company's planned use of proceeds resulting from the concurrent New Notes offering). These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: risks and uncertainties related to the completion of the Tender Offers and the concurrent New Notes offering on the anticipated terms or at all, applicable market conditions, the satisfaction of customary closing conditions related to Tender Offers (including the Financing Condition), the Company's ability to achieve the intended benefits of its recent strategic actions, including the sale of the Kidney Care business, business strategy and development activities (including the acquisition Hill-Rom Holdings, Inc. and completion of related integration activities) and cost saving initiatives, or of future long-term financial improvement goals; the impact of global economic conditions (including, among other things, changes in tariffs, taxation, trade policies and treaties, sanctions, embargos, export control restrictions, the potential for a recession, supply chain disruptions, inflation levels and interest rates, financial market volatility, banking crises, the war in Ukraine, the conflict in the Middle East and other geopolitical events, and the potential for escalation of these and other conflicts, the related economic sanctions being imposed globally in response to the conflicts and potential trade wars, global public health crises, pandemics and epidemics, or the anticipation of any of the foregoing, on the Company's operations and on the Company's employees, customers, suppliers, and foreign governments in countries in which the Company operates and the Company's ability to identify actions to mitigate the impact of those conditions (or to realize the anticipated benefits of any such mitigating actions); demand and market acceptance risks for, and competitive pressures (including pricing) related to, new and existing products and services (including customer response to recent Novum IQ Large Volume Pump (Novum LVP) field actions and the related voluntary ship and installation hold, which may include additional returns or exchanges), challenges and reputational risks associated with converting customers to new or alternative products and challenges with accurately predicting changing customer preferences and future expenditures and inventory levels (including with respect to the impact of the Novum LVP ship and installation hold and what the Company believes to be continuing fluid conservation practices) and with being able to monetize new and existing products and services, the impact of those products and services on quality and patient safety concerns, and the need for ongoing training and support for the Company's products and services; product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or resubmission of any pending applications), the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle (which may result in monetary penalties owed to the Company's suppliers in the event the Company does not place orders at levels contemplated in its contractual arrangements); future actions of, or failures to act or delays in acting by the U.S. Food and Drug Administration, the European Medicines Agency, or any other regulatory* 

------

*body or government authority (including the U.S. Securities and Exchange Commission, Department of Justice, Health Canada or the Attorney General of any state), or any product quality or patient safety issues (including those related to the Company's infusion pump category) that could delay, limit or suspend product development, manufacturing, or sale or otherwise lead to product recalls (either voluntary or required by governmental authorities), adverse regulatory site inspection reports, voluntary or official action indicated classifications, labeling changes, launch delays, warning letters, import bans, refusal of a government to grant or the government withdrawal of approvals, clearances, licenses or other marketing authorizations, denial of import certifications, sanctions, seizures, injunctions (including to halt manufacture or distribution), monetary sanctions, criminal or civil liabilities or litigation; the continuity, availability, and pricing of acceptable raw materials and component parts, the Company's ability to pass some or all of any increased costs to its customers through price increases or otherwise, and the related continuity of the Company's manufacturing, sterilization, supply and distribution and those of the Company's suppliers; failure to accurately forecast or achieve the Company's short- and long-term financial performance and goals, market and category growth rates, growth rates for the Company's segments, customer demand and related impacts on the Company's liquidity (including with respect to increased inventory levels); the Company's ability to execute on its capital allocation plans, including the Company's debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds; future downgrades to the Company's credit ratings or ratings outlooks, or withdrawals by rating agencies from rating the Company and its indebtedness, and the related impact on the Company's funding costs and liquidity; the Company's ability to finance and develop new products or services, or enhancements thereto, on commercially acceptable terms or at all; actions by tax authorities in connection with ongoing tax audits (including with respect to transfer pricing matters and the potential issuance of one or more Notice of Proposed Adjustments), the outcome of pending or future litigation (including as a result of customer or supplier disputes) and the sufficiency of any related reserves; fluctuations in foreign exchange and interest rates; the impact of any accounting estimates and assumptions, including with respect to goodwill, intangible assets, or other long-lived asset impairments on the Company's operating results; failures with respect to the Company's quality, compliance or ethics programs; our ability to attract, develop, retain and engage key employees, including as a result of recent organizational or other corporate changes and strategic initiatives and those that may be made in the future, and the occurrence of labor disruptions resulting from labor disagreements under bargaining agreements or national trade union agreements, disputes with works councils or otherwise); inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization, or supply difficulties, including as a result of natural disaster or severe weather event (such as Hurricane Helene), war, terrorism, global public health crises and epidemics/pandemics, regulatory actions, or otherwise; future actions of third parties, including third-party payors and the Company's customers and distributors (including group purchasing organizations and integrated delivery networks); breaches and breakdowns affecting the Company's information technology systems or protected information, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or vulnerabilities in the Company's information technology systems or products; the Company's ability to effectively develop, integrate or deploy artificial intelligence, machine learning and other emerging technologies into the Company's products, services and operations in a manner that is compliant with existing and emerging regulations and consistent with evolving customer preferences; the impact of physical effects of climate change, severe storms (including Hurricane Helene) and storm-related events; changes to legislation and regulation and other governmental pressures in the United States and globally, including the cost of compliance and potential penalties for purported noncompliance thereof, including new or amended laws, rules and regulations as well as the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation (including taxation of income, whether with respect to current or future tax reform) and rebate policies; the Company's ability to meet evolving and varied corporate responsibility expectations of the Company's stakeholders, including compliance with emerging and potentially contradictory global sustainability regulations; the ability to protect or enforce the Company's patents or other proprietary rights (including trademarks, copyrights, trade secrets, and know-how) or where the patents of third parties prevent or restrict the Company's manufacture, sale, or use of affected products or technology; and other factors discussed in Baxter's most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on* 

------

*Baxter's website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws.*

Baxter and Novum IQ are trademarks of Baxter International Inc.

------

**Media Contact:**

Stacey Eisen, (224) 948-5353

media@baxter.com

**Investor Contact:**

Kevin Moran, (224) 948-3085

global_corp_investor_relations@baxter.com

<br>